Coalition for Epidemic Preparedness Innovations (CEPI) [to 26 November 2106]
CEPI Newsletter 21 November 2016
CEPI policies – invitation to feedback
Over the last two months, the CEPI Secretariat has been working with colleagues from the
founding partners to draft CEPI’s core policies to reflect CEPI’s operating principles and
provide guidance for potential awardees during the call for proposal process. The team
has also consulted with individuals working with Product Development Partnerships
and researchers in this field.
We now invite your comments and feedback on these draft policies on equitable access,
shared risks/benefits and management of IP http://cepi.net/resources#CEPI-Policies-Draft
. The open public consultation period is from today through to COB CET 2 December,
2016. Please send feedback to firstname.lastname@example.org.
Following receipt of feedback during the open public consultation period, the Secretariat
will amend the policies as required and submit them to the CEPI Board for approval prior
to their release with the call for proposals.
EDCTP [to 26 November 2106]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials.
23 November 2016
Stakeholder meeting reports published: diarrhoeal diseases and lower respiratory tract infections
EDCTP published two reports of the stakeholder meetings on diarrhoeal diseases and lower respiratory tract infections, respectively. The meetings for these fields added to our scope under the second programme took place in Amsterdam, The Netherlands on 5 and 6 July 2016. Their aim was to consult experts in these fields in order to inform EDCTP’s funding strategy and future work plans related to these disease areas.. Representatives from academic and research institutions, funding agencies, product development partnerships among others were invited to participate.
On 5 July 2016, Prof. Philippe Sansonetti (Institut Pasteur and Collège de France, France) and Dr Jeffrey Mphahlele (South African Medical Research Council, South Africa) chaired the meeting on diarrhoeal diseases which featured three speakers and sessions with focus groups. Download report (PDF)
On 6 July 2016, Prof. Jeremy Brown (University College London, United Kingdom) steered the discussions on lower respiratory tract infections in response to six speakers. Download report (PDF)
The objectives of both meetings were to review the research landscape, available interventions and products in development, and to identify short and medium term priorities for EDCTP in terms of disease, research and intervention.
EDCTP regularly organises thematic stakeholder meetings as part of its ongoing consultation process. The purpose of thematic stakeholder meetings is to contribute to shaping the programme’s strategic research agenda, funding approach and strategic alignment with work of other partners involved in clinical development of interventions against poverty-related diseases.
Industry Watch [to 26 November 2106]
:: GSK receives FDA approval for expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 months and older
PHILADELPHIA, Nov. 21, 2016 /PRNewswire/ — GSK [LSE/NYSE: GSK] announced today it has received approval from the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research expanding the indication for FluLaval® Quadrivalent (Influenza Vaccine) to include use in children 6 months and older. Prior to this, the vaccine was only approved for active immunization against influenza A subtype viruses and type B viruses, in persons 3 years of age and older…
IFPMA [to 26 November 2106]
23 November 2016
International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) head announces departure
Geneva, 23 November 2016 – After seven years as Director General, Eduardo Pisani announced today his decision to leave the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)…
European Vaccine Initiative [to 26 November 2106]
25 November 2016
Call for abstracts- 2017 SVS skin vaccination summit
The deadline for oral abstract submissions is Friday 2nd December 2016.
25 November 2016
New influenza reagents available from NIBSC
Two new influenza reagents are now available. Influenza anti-A/Michigan/45/2015-like HA serum and Influenza Antigen A/…